Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

A method of protecting the health of a subject of age 60 or older, an immunocompromised subject, or a subject suffering from a respiratory and/or cardiovascular disorder that is infected with or at risk of infection with SARS-COV-2 comprising administering to the subject a first antibody or antibody fragment comprising:

• (a) a CDRH1 comprising the amino acid sequence of SEQ ID NO:59, a CDRH2 comprising the amino acid sequence of SEQ ID NO:60, a CDRH3 comprising the amino acid sequence of SEQ ID NO:61, a CDRL1 comprising the amino acid sequence of SEQ ID NO:
• 89, a CDRL2 comprising the amino acid sequence of SEQ ID NO:90, a CDRL3 comprising the amino acid sequence of SEQ ID NO:91;
• (b) a CDRH1 comprising the amino acid sequence of SEQ ID NO:68, a CDRH2 comprising the amino acid sequence of SEQ ID NO:69, a CDRH3 comprising the amino acid sequence of SEQ ID NO:70, a CDRL1 comprising the amino acid sequence of SEQ ID NO:
• 98, a CDRL2 comprising the amino acid sequence of SEQ ID NO:99, a CDRL3 comprising the amino acid sequence of SEQ ID NO:
• 100;
• (c) a CDRH1 comprising the amino acid sequence of SEQ ID NO:41, a CDRH2 comprising the amino acid sequence of SEQ ID NO:42, a CDRH3 comprising the amino acid sequence of SEQ ID NO:43, a CDRL1 comprising the amino acid sequence of SEQ ID NO:
• 71, a CDRL2 comprising the amino acid sequence of SEQ ID NO:72, a CDRL3 comprising the amino acid sequence of SEQ ID NO:73;
• (d) a CDRH1 comprising the amino acid sequence of SEQ ID NO:44, a CDRH2 comprising the amino acid sequence of SEQ ID NO:45, a CDRH3 comprising the amino acid sequence of SEQ ID NO:46, a CDRL1 comprising the amino acid sequence of SEQ ID NO:
• 74, a CDRL2 comprising the amino acid sequence of SEQ ID NO:75, a CDRL3 comprising the amino acid sequence of SEQ ID NO:76;
• (e) a CDRH1 comprising the amino acid sequence of SEQ ID NO:47, a CDRH2 comprising the amino acid sequence of SEQ ID NO:48, a CDRH3 comprising the amino acid sequence of SEQ ID NO:49, a CDRL1 comprising the amino acid sequence of SEQ ID NO:
• 77, a CDRL2 comprising the amino acid sequence of SEQ ID NO:78, a CDRL3 comprising the amino acid sequence of SEQ ID NO:79;
• (f) a CDRH1 comprising the amino acid sequence of SEQ ID NO:50, a CDRH2 comprising the amino acid sequence of SEQ ID NO:51, a CDRH3 comprising the amino acid sequence of SEQ ID NO:52, a CDRL1 comprising the amino acid sequence of SEQ ID NO:
• 80, a CDRL2 comprising the amino acid sequence of SEQ ID NO:81, a CDRL3 comprising the amino acid sequence of SEQ ID NO:82;
• (g) a CDRH1 comprising the amino acid sequence of SEQ ID NO:53, a CDRH2 comprising the amino acid sequence of SEQ ID NO:54, a CDRH3 comprising the amino acid sequence of SEQ ID NO:55, a CDRL1 comprising the amino acid sequence of SEQ ID NO:
• 83, a CDRL2 comprising the amino acid sequence of SEQ ID NO:84, a CDRL3 comprising the amino acid sequence of SEQ ID NO:85;
• (h) a CDRH1 comprising the amino acid sequence of SEQ ID NO:56, a CDRH2 comprising the amino acid sequence of SEQ ID NO:57 a CDRH3 comprising the amino acid sequence of SEQ ID NO:58, a CDRL1 comprising the amino acid sequence of SEQ ID NO:
• 86, a CDRL2 comprising the amino acid sequence of SEQ ID NO:87, a CDRL3 comprising the amino acid sequence of SEQ ID NO:88;
• (i) a CDRH1 comprising the amino acid sequence of SEQ ID NO:62, a CDRH2 comprising the amino acid sequence of SEQ ID NO:63 a CDRH3 comprising the amino acid sequence of SEQ ID NO:64, a CDRL1 comprising the amino acid sequence of SEQ ID NO:
• 65, a CDRL2 comprising the amino acid sequence of SEQ ID NO:66, a CDRL3 comprising the amino acid sequence of SEQ ID NO:67;
• or
• (j) a CDRH1 comprising the amino acid sequence of SEQ ID NO:65, a CDRH2 comprising the amino acid sequence of SEQ ID NO:66, a CDRH3 comprising the amino acid sequence of SEQ ID NO:67, a CDRL1 comprising the amino acid sequence of SEQ ID NO:
• 95, a CDRL2 comprising the amino acid sequence of SEQ ID NO:96, a CDRL3 comprising the amino acid sequence of SEQ ID NO:97.

A method of reducing the likelihood of infection of a subject at risk of contracting SARS-COV-2, comprising administering to the subject a first antibody or antibody fragment and a second antibody or antibody fragment, wherein the first antibody or antibody fragment comprises a CDRH1 comprising the amino acid sequence of SEQ ID NO:

• 59, a CDRH2 comprising the amino acid sequence of SEQ ID NO:60, a CDRH3 comprising the amino acid sequence of SEQ ID NO:61, a CDRL1 comprising the amino acid sequence of SEQ ID NO:89, a CDRL2 comprising the amino acid sequence of SEQ ID NO:
• 90, a CDRL3 comprising the amino acid sequence of SEQ ID NO:91, and wherein the second antibody or antibody fragment comprises a CDRH1 comprising the amino acid sequence of SEQ ID NO:68, a CDRH2 comprising the amino acid sequence of SEQ ID NO:
• 69, a CDRH3 comprising the amino acid sequence of SEQ ID NO:70, a CDRL1 comprising the amino acid sequence of SEQ ID NO:98, a CDRL2 comprising the amino acid sequence of SEQ ID NO:99, a CDRL3 comprising the amino acid sequence of SEQ ID NO:
• 100.